Educational analysis only — not financial advice. Always do your own due diligence.
DHR trades against a final fair-value range of $122.72-$203.68, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Under severe bioprocessing market contraction and failed M&A execution, our pure intrinsic models force valuation toward the $114-$122 range. Margins revert below 19% as DBS efficiencies fail to offset volume deleverage, and the terminal multipleTerminal multipleThe exit P/E or EV/EBITDA we apply to the final year of an explicit forecast. Anchored to the business's long-run quality and the prevailing risk-free rate. contracts toward 15x as the compounding narrative breaks.
Extended pharma funding constraints and destocking cap revenue growth in low single-digits.
A major acquisition fails to realize DBS synergies, destroying ROIC and stalling margin expansion.
Deepening macro weakness and localized competition in China structurally erode regional market share and profitability.
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net income, accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
